Most Common Cancers That Metastasize to the Brain
Lung cancer is the most common cancer that metastasizes to the brain, accounting for approximately 43% of all brain metastases, followed by breast cancer (20%) and melanoma (8%). 1, 2, 3
Primary Cancer Distribution
The three dominant primary cancers responsible for brain metastases are:
- Lung cancer: 43% - This includes both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with SCLC showing particularly high rates (approximately 80% of patients develop brain metastases by autopsy) 2
- Breast cancer: 19.9% - Notably, among patients with HER2-positive breast cancer who die, approximately 50% develop intracranial metastases by the time of death 2
- Melanoma: 8.2% - Shows the highest point prevalence at initial diagnosis, with over 25% of metastatic melanoma patients having brain metastases at diagnosis 1
Additional Common Sources
After the "big three," the next most frequent primary sites include:
- Renal cell carcinoma: 5% 3
- Colorectal cancer: 3.8% 3
- Gastrointestinal primaries: 2-5% (depending on specific site) 1
Important Clinical Context
The incidence of brain metastases varies dramatically by cancer subtype and screening practices. For metastatic lung adenocarcinoma, over 25% have brain metastases at initial diagnosis, compared to only 2% for non-esophageal gastrointestinal cancers 1. This disparity reflects both biological tropism and differential screening practices - lung cancer, melanoma, and testicular cancer patients undergo routine brain screening, while breast, renal, and gastrointestinal cancer patients typically do not 2.
Among patients with lung cancer, approximately 20% develop brain metastases within the first year after diagnosis 1. This high early incidence explains why lung cancer dominates the brain metastasis landscape despite breast cancer being more prevalent overall.
Temporal Trends
Recent data from 2008-2018 shows the proportion of brain metastases from breast cancer decreased by 23.8% and from melanoma by 46.7%, likely reflecting improved systemic therapies that provide better CNS control 3. Conversely, brain metastases from rare primary sites increased by 34.4% during this period 3.